08/19/2026
Standard of Care Spotlight: Anticoagulant Management Before Interventional Spine Procedures
Welcome back to Standard of Care Spotlight, where I share evidence-based insights from my expert witness work.
Today’s topic: managing anticoagulant and antiplatelet medications before interventional spine procedures.
Inadequate peri-procedural management can lead to serious complications, including spinal epidural hematoma, stroke, myocardial infarction, pulmonary embolism, and death. The goal is not simply to “stop the blood thinner,” but to appropriately balance bleeding and thrombotic risks.
The 2022 ASRA Pain Medicine Guidelines and updated 2024 ASIPP Guidelines emphasize individualized, procedure-specific decision-making.
Key Practice Pearls
• Know the procedure risk. Low-, intermediate-, and high-risk procedures require different considerations.
• Know the medication. Warfarin, DOACs, aspirin, clopidogrel, and other agents have different pharmacologic profiles and management recommendations.
• Assess thrombotic risk. Patients with mechanical heart valves, atrial fibrillation, recent VTE, coronary stents, or other high-risk conditions may require coordination with the prescribing specialist.
• Document the decision. Record the rationale for continuing or withholding medication, including risks, benefits, and alternatives.
• Have a complication plan. Practices should be prepared to recognize and respond to spinal epidural hematoma, including urgent imaging and neurosurgical consultation.
Takeaway
Safe anticoagulant management is not about memorizing medication hold times. It requires risk stratification, communication, documentation, and individualized clinical judgment.
In my expert witness work, I frequently find that litigation centers not only on the complication, but on whether the clinical decision-making process was appropriately documented.
Follow for more insights from my expert witness work.
If you or your firm need expert witness support in anesthesia or pain management cases, reach out.
